Cytomegalovirus-based immunogenic preparations

A technology of cytomegalovirus and human cytomegalovirus, applied in the direction of antiviral agents, viruses, viruses/phages, etc., can solve the problems of restricting the use of CMV tumor vaccines and becoming immunodeficiency

Inactive Publication Date: 2012-12-26
OREGON HEALTH & SCI UNIV
View PDF17 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although CMV infection is usually completely asymptomatic in healthy individuals, it can be problematic in immunosuppressed individuals such as AIDS patients, organ transplant recipients, or infants infected in utero
Furthermore, potential recipients of CMV-based tumor vaccines may be or may become immunocompromised, thereby significantly limiting the use of live CMV tumor vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cytomegalovirus-based immunogenic preparations
  • Cytomegalovirus-based immunogenic preparations
  • Cytomegalovirus-based immunogenic preparations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0195] Example 1: Antitumor efficacy of CMV-loaded antigen-primed CTLs

[0196] A major challenge in developing effective anti-tumor vaccines is overcoming the inability of the immune system to distinguish tumors from self-proteins. More recently, attempts to develop a heritable immuno-sterility control for wild mice have shown that normal self-proteins expressed in recombinant CMV vectors have the potential to become antigenic (Lloyd et al., Biol. Reprod. 68:2024-2032, 2003 and Redwood et al., J. Virol. 79:2998-3008, 2005). In this study, the native sequence of murine zona pellucida 3 (ZP3), a normal mouse protein, was introduced into MCMV behind the immediate early 2 (IE2) promoter. Strikingly, a single inoculation of the virus rendered female mice completely sterile for the length of time as observed (>230 days).

[0197]This example demonstrates that tumor-expressed self-antigens also become immunogenic when expressed in the context of CMV. The therapeutic capacity of t...

Embodiment 2

[0206] Example 2: Infection with replication-deficient ΔgL MCMV elicits durable immunogenic priming and expansion of T cell memory

[0207] On average, humans contribute their memory CD8 to CMV + 10% of the T cell compartment. Research in recent years has revealed that this extraordinary immune response to CMV infection involves several stages. In initial CD8 + Following the T cell response, the T cell response to MCMV begins to decline to the characteristic "memory" level (Munks et al., J. Immunol. 176:3760-3766, 2006). However, it then begins a remarkable process called "memory expansion" (Karrer et al., J. Immunol. 170:2022-2029, 2003 and Munks et al., J. Immunol. 177:450-458, 2006). For a period of several months, CD8 T cell responses to specific epitopes increased in number, eventually plateauing at higher levels such that the total CMV-specific response contained between 10% and 30% CD8 + T cells.

[0208] This example demonstrates that replication-defective MCMVs i...

Embodiment 3

[0221] Example 3: Lack of expansion of T cell memory in response to subcutaneous ΔgL MCMV infection

[0222] As shown in Example 2, CD8 + T cell memory expansion is driven by intraperitoneal infection of mice with wild-type and ΔgLMCMV. It is believed that the ability of ΔgL MCMV to elicit long-lasting self-excited T cell memory is a consequence of establishing CMV latency in HSCs. Thus, any administration of CMV that exposes the virus to HSCs (eg, intravenous administration) will similarly trigger the characteristic expansion of T cell memory. This example shows that subcutaneous administration of replication deficient MCMV failed to detect expansion of T cell memory.

[0223] method

[0224] Mice were infected as in Example 1 and Example 2. However, in this example, mice were anesthetized with isoflurane and infected with either wild-type or ΔgL MCMV by a single injection into the left hind footpad. T cell responses to wild-type and ΔgL MCMV in peripheral blood were det...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This disclosure relates to methods of using recombinant replication-deficient cytomegalovirus (CMV) to generate a long-term, repeatedly stimulated T cell-based immune response in a subject, for instance against a heterologous antigen expressed by the cytomegalovirus. It further relates to methods of using a recombinant replication deficient CMV as an anti-cancer immunogenic preparation.

Description

technical field [0001] The present invention relates to methods of using recombinant replication-deficient cytomegalovirus (CMV) to generate a long-term, permanently activated T cell-based immune response in a subject, such as an immune response against a heterologous antigen expressed by cytomegalovirus . The invention further relates to methods of using recombinant replication-deficient CMV as immunogenic agents against cancer. [0002] statement of government support [0003] This invention was made with government support under Grant Nos. RO1AI 47206 and 21CA12718 awarded by the NIH and Grant No. BC084377 awarded by the Department of Defense. The government has certain rights in this invention. Background technique [0004] While there are clear parallels between oncology and viral immunology, their differences are even more pronounced in their fields. Viruses are generally potent immunogenic, activate innate immune "danger" signals (eg, Toll-like receptor signaling)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/569C07K14/045G01N33/574G01N33/15A61K39/00
CPCA61K2039/57A61K39/0011A61K2039/5256C12N7/00A61K2039/5254C12N2710/16161A61P31/04A61P31/10A61P31/12A61P35/00A61K45/06A61K48/00A61K2039/54A61K2039/545A61K2039/575A61N5/10C12N15/86C12N2710/16121C12N2710/16134C12N2710/16142
Inventor A·B·希尔C·M·斯奈德
Owner OREGON HEALTH & SCI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap